Fluicell Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Fluicell
Access all reports
Fluicell is a biotech company that specializes in pioneering solutions for bioprinting and single-cell biology. Established in 2012 as a spin-off from Chalmers University of Technology in Gothenburg, Sweden, Fluicell has developed a reputation for its innovative approach to studying and manipulating individual cells with precision. The company's flagship technology, Biopixlar, is a high-resolution 3D bioprinting platform capable of constructing biological tissues at the single-cell level without the need for bioink. This technology is utilized in the development of tissue-based therapies for serious diseases lacking adequate treatments, such as type 1 diabetes, cardiovascular disease, and kidney disease.
Latest articles
Dick Smith: The Orchestrator of General Cinema's Expansion
Explore the genius of Dick Smith in revolutionizing General Cinema, as highlighted in “The Outsiders”.
8 May 2024
Alex Karp: The Unconventional Tech Visionary
Explore how Alex Karp's unique blend of ethical leadership and personal well-being shapes his role as CEO of Palantir Technologies.
8 May 2024
From Timber to Luxury: The Story of François-Henri Pinault and Kering
Dive into the story of François-Henri Pinault, from his rise in the family timber business to leading Kering into a global luxury powerhouse.
7 May 2024
Ticker symbol
Country
🇸🇪 Sweden